Multicenter Phase II trial of Irinotecan plus S-1 with cetuximab (IRIS/Cet) in patients with EGFR positive and KRAS wild type of advanced/metastatic colorectal cancer.
Phase of Trial: Phase II
Latest Information Update: 02 Jul 2016
At a glance
- Drugs Cetuximab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- 15 Jul 2015 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 15 Jan 2014 Status changed from recruiting to active, no longer recruiting.
- 15 Jul 2013 Planned end date changed from 1 Jun 2012 to 1 Dec 2014 as reported by University Hospital Medical Information Network - Japan.